SPIA
PRTK

Steward Partners Investment Advisory’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Steward Partners Investment Advisory’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-400
Closed -$1K – 2788
2019
Q3 		$1K Hold
400
– – ﹤0.01% 2571
2019
Q2 		$1K Buy
+400
New +$1.9K ﹤0.01% 2571

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steward Partners Investment Advisory's PRTK Position: Q4 2019 in Review

Steward Partners Investment Advisory sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2019, closing a stake of 400 shares — an estimated $1K sold.

Steward Partners Investment Advisory first reported a position in PRTK in Q2 2019 and held it in 2 quarters. The position peaked at $1K in Q3 2019. 93 funds tracked by Wall St. Rank hold PRTK as of Q4 2019.

  • Steward Partners Investment Advisory reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 400 Paratek Pharmaceuticals, Inc. shares in Q4 2019, an estimated $1K.
  • Steward Partners Investment Advisory first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2019 and held it in 2 quarters.
  • Steward Partners Investment Advisory's Paratek Pharmaceuticals, Inc. position peaked at $1K in Q3 2019.
  • 93 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2019.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2019, filed 17 Jan 2020.